Meli Rosaria, Mattace Raso Giuseppina, Calignano Antonio
Department of Pharmacy, University of Naples "Federico II" , Naples , Italy.
Front Immunol. 2014 Apr 23;5:177. doi: 10.3389/fimmu.2014.00177. eCollection 2014.
Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver disease worldwide, both in adults and children. It is characterized by an aberrant lipid storage in hepatocytes, named hepatic steatosis. Simple steatosis remains a benign process in most affected patients, while some of them develop superimposed necroinflammatory activity with a non-specific inflammatory infiltrate and a progression to non-alcoholic steatohepatitis with or without fibrosis. Deep similarity and interconnections between innate immune cells and those of liver parenchyma have been highlighted and showed to play a key role in the development of chronic liver disease. The liver can be considered as an "immune organ" because it hosts non-lymphoid cells, such as macrophage Kupffer cells, stellate and dendritic cells, and lymphoid cells. Many of these cells are components of the classic innate immune system, enabling the liver to play a major role in response to pathogens. Although the liver provides a "tolerogenic" environment, aberrant activation of innate immune signaling may trigger "harmful" inflammation that contributes to tissue injury, fibrosis, and carcinogenesis. Pathogen recognition receptors, such as toll-like receptors and nucleotide oligomerization domain-like receptors, are responsible for the recognition of immunogenic signals, and represent the major conduit for sensing hepatic and non-hepatic noxious stimuli. A pivotal role in liver inflammation is also played by cytokines, which can initiate or have a part in immune response, triggering hepatic intracellular signaling pathways. The sum of inflammatory signals and deranged substrate handling induce most of the metabolic alteration traits: insulin resistance, obesity, diabetes, hyperlipidemia, and their compounded combined effects. In this review, we discuss the relevant role of innate immune cell activation in relation to NAFLD, the metabolic complications associated to this pathology, and the possible pharmacological tools.
非酒精性脂肪性肝病(NAFLD)是目前全球范围内成人和儿童中最常见的肝脏疾病。其特征是肝细胞中出现异常脂质蓄积,即肝脂肪变性。在大多数受影响的患者中,单纯性脂肪变性仍是一个良性过程,而其中一些患者会出现叠加的坏死性炎症活动,伴有非特异性炎症浸润,并进展为非酒精性脂肪性肝炎,伴或不伴有纤维化。固有免疫细胞与肝实质细胞之间的高度相似性和相互联系已得到强调,并显示在慢性肝病的发展中起关键作用。肝脏可被视为一个“免疫器官”,因为它含有非淋巴细胞,如巨噬细胞库普弗细胞、星状细胞和树突状细胞,以及淋巴细胞。这些细胞中的许多是经典固有免疫系统的组成部分,使肝脏能够在应对病原体方面发挥主要作用。尽管肝脏提供了一个“耐受性”环境,但固有免疫信号的异常激活可能引发“有害”炎症,导致组织损伤、纤维化和致癌作用。病原体识别受体,如Toll样受体和核苷酸寡聚化结构域样受体,负责识别免疫原性信号,是感知肝脏和非肝脏有害刺激的主要途径。细胞因子在肝脏炎症中也起着关键作用,它们可以启动或参与免疫反应,触发肝脏细胞内信号通路。炎症信号和紊乱的底物处理共同导致了大多数代谢改变特征:胰岛素抵抗、肥胖、糖尿病、高脂血症及其复合效应。在本综述中,我们讨论了固有免疫细胞激活与NAFLD相关的作用、与该病理相关的代谢并发症以及可能的药物治疗手段。